MSME (Udyam registered) Ministry of MSME
- Category
- Micro (2023-24)
- Udyam number
- UDYAM-UP-76-0006686
Novorem Pharmaceuticals Private Limited
Novorem Pharmaceuticals Private Limited - trading in New Delhi, Delhi, India. FY 2026 financials & compliance.
Revenue · FY 2025
₹2.53 Cr
▲ 16% YoY
Net profit · FY 2025
₹1.89 Lakh
Net margin 0.7%
EBITDA · FY 2025
₹2.86 Lakh
EBITDA margin 1.1%
Authorised capital
₹5 Lakh
Registered with MCA
Paid-up capital
₹5 Lakh
Issued & subscribed
Open charges
₹99 Lakh
Secured borrowings
Company age
14 yrs
Est. 2012
Directors on board
2
As per MCA filings
About Novorem Pharmaceuticals Private Limited
Data last updated:
Novorem Pharmaceuticals Private Limited is a private limited company based in New Delhi, Delhi, India. It operates in the wholesale distribution segment of the trading and commerce sector. It was incorporated on 28 December 2012 and has been in existence for over 14 years.
The company is registered with the Registrar of Companies (ROC), Delhi, under CIN U51397DL2012PTC246789. Its GSTIN is 09AAECN2302H1ZS (Uttar Pradesh).
The company has an authorised share capital of ₹5 Lakh and a paid-up capital of ₹5 Lakh. It is led by directors Samiullah Khan (Managing Director) and Fatima (Whole-Time Director).
Its last annual general meeting (AGM) was held on 30 July 2025, and its latest financial statements are for the year ended 31 March 2025. The registered office is at B – 10 Choudhary Complex D – 54 Main Road Batla House Jamia Naga, R, New Delhi, Delhi, India – 110025.
As per the financials filed for FY 2025, the company reported a revenue of ₹2.53 Cr, a growth of 16% compared to the previous year. For the same year it recorded a net profit of ₹1.89 Lakh (net margin 0.7%) and EBITDA of ₹2.86 Lakh (EBITDA margin 1.1%). Revenue has grown at a compounded annual rate (CAGR) of 9% over three years and 6% over five years.
As per MCA filings, the company has open charges of ₹99 Lakh on record.
Novorem Pharmaceuticals Private Limited is registered as a micro enterprise under the Udyam registration framework (Reg. No. UDYAM-UP-76-0006686). The current compliance status is marked as compliant by the Registrar of Companies.
Company details
CIN U51397DL2012PTC246789
Registration Number 246789
Incorporation Date 28 December 2012
ROC Delhi
Listing Status Unlisted
Company Status Active
Date of Last AGM 30 July 2025
Date of Balance Sheet 31 March 2025
Compliance Status Active Compliant
MSME Classification Micro
Udyam Registration UDYAM-UP-76-0006686
Recognitions & Rankings of Novorem Pharmaceuticals
Contact details
Novorem Pharmaceuticals Private Limited's registered office is in New Delhi, Delhi. Its e-mail address and telephone number are in the company report.
- Email
- Telephone
- Registered AddressB – 10 Choudhary Complex D – 54 Main Road Batla House Jamia Naga, R, New Delhi, Delhi, India – 110025
- IndustryTrading, Other Wholesale, Wholesale
To see the full contact details of Novorem Pharmaceuticals Private Limited, buy the company report.
Comprehensive company report
Novorem Pharmaceuticals Private Limited - one report that includes everything
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
₹799 ₹999 20% off excluding 18% GST
Secure checkout · GST invoice included
Business activity
The main business activity of Novorem Pharmaceuticals is trade. In detail, this covers wholesale trading.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| G | Trade | G1 | Wholesale Trading |
To see the full business activity and turnover split of Novorem Pharmaceuticals Private Limited, buy the company report.
Financials of Novorem Pharmaceuticals Private Limited
FY 2025 filings availableNovorem Pharmaceuticals Private Limited reported revenue of ₹2.53 Cr (up 16% YoY) for FY 2025.
Revenue · FY 2025
₹2.53 Cr ▲ 16%
Net profit · FY 2025
₹1.89 Lakh margin 0.7%
EBITDA · FY 2025
₹2.86 Lakh margin 1.1%
Compounded Annual Growth Rate (CAGR)
Revenue CAGR growth
1 year
▲ 16%
3 years · compounded
▲ 9%
5 years · compounded
▲ 6%
EBITDA CAGR growth
1 year
▲ 17%
3 years · compounded
▲ 14%
5 years · compounded
▼ 16%
Revenue has grown at a compounded annual rate (CAGR) of 6% over five years, including 16% growth in the latest year. EBITDA rose 17% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.
Financial Statement Summary
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profit and Loss Statement | |||||
| Revenue from Operations | |||||
| Other Income | |||||
| Total Revenue | |||||
| Cost of Materials Consumed | |||||
| Employee Benefit Expense | |||||
| Finance Costs | |||||
| Depreciation and Amortisation | |||||
| Other Expenses | |||||
| Total Expenses | |||||
| EBITDA | ₹2.86 Lakh | ||||
| Profit Before Tax | |||||
| Tax Expense | |||||
| Net Profit (PAT) | ₹1.89 Lakh | ||||
| Balance Sheet | |||||
| Share Capital | |||||
| Reserves and Surplus | |||||
| Net Worth (Total Equity) | |||||
| Long-term Borrowings | |||||
| Short-term Borrowings | |||||
| Trade Payables | |||||
| Total Liabilities | |||||
| Fixed Assets | |||||
| Investments | |||||
| Inventories | |||||
| Trade Receivables | |||||
| Cash and Bank Balance | |||||
| Total Assets | |||||
Financial Ratios
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profitability | |||||
| EBITDA Margin | 1.1% | ||||
| Net Profit Margin | 0.7% | ||||
| Return on Equity (ROE) | |||||
| Return on Capital Employed (ROCE) | |||||
| Return on Assets (ROA) | |||||
| Liquidity and Debt | |||||
| Current Ratio | |||||
| Quick Ratio | |||||
| Debt-to-Equity Ratio | |||||
| Interest Coverage Ratio | |||||
| Efficiency and Growth | |||||
| Asset Turnover | |||||
| Receivable Days | |||||
| Payable Days | |||||
| Inventory Days | |||||
| Revenue Growth | |||||
| Net Profit Growth | |||||
To see the full financial statements and ratios of Novorem Pharmaceuticals Private Limited, buy the company report.
Board of directors of Novorem Pharmaceuticals Private Limited
Novorem Pharmaceuticals has 2 current directors and 2 former directors. Current directors are listed first, with their designation and appointment date.
Current Directors
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Samiullah Khan Also directs: Novorem Pharmacy (OPC) Private Limited | Managing Director | 28 Dec 2012 | 13 Years 9 Months | Current |
| Fatima | Whole-Time Director | 14 Sep 2018 | 8 Years 1 Months | Current |
Auditor
Novorem Pharmaceuticals Private Limited is audited by S. N. GARG & CO. for the financial year 2017.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| S. N. GARG & CO. | FY 2017 | 02207C |
Shareholding
The shareholding of Novorem Pharmaceuticals Private Limited is on record for 2 financial years, the latest being FY 2017, split between promoters, domestic institutions, foreign institutions, public shareholders and others.
| Shareholder category | FY 2017 | FY 2016 |
|---|---|---|
| Promoters | ||
| Domestic institutional investors (DII) | ||
| Foreign institutional investors (FII) | ||
| Public | ||
| Others |
To see the full shareholding pattern of Novorem Pharmaceuticals Private Limited, buy the company report.
Charges & borrowings
Open charges
₹99 Lakh
Satisfied charges
None
Breakdown by lending institutions
Latest charge details
| Date | Charge ID | Lender | Amount | Status | Modified or satisfied on |
|---|---|---|---|---|---|
| 29 Jan 2020 | 100326414 | Canara Bank | ₹99 Lakh | Open |
To see the full charge records of Novorem Pharmaceuticals Private Limited, buy the company report.
Total charge records: 1 View all charges
Legal cases
No court or tribunal cases involving Novorem Pharmaceuticals Private Limited are on our record; a case search with case numbers, parties and status is in the company report Buy the company report.
MSME payment delays
No delayed payments to MSME suppliers are on our record for Novorem Pharmaceuticals Private Limited; the supplier-wise MSME Form 1 check is in the company report Buy the company report.
GST
Novorem Pharmaceuticals has 1 GST registration: 1 active.
Total GSTINs
1
Active
1
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 09AAECN2302H1ZS | Uttar Pradesh | Active | 01 Jul 2017 |
To see the full GST registrations and return filing status of Novorem Pharmaceuticals Private Limited, buy the company report.
Recent activity
Novorem Pharmaceuticals Private Limited has 3 board changes on record since 2012: 2 appointments and 1 cessation. The latest: Fatima was appointed as Whole-Time Director on 14 Sep 2018.
AGM
Novorem Pharmaceuticals Private Limited last Annual general meeting of members was held on 30 Jul 2025 as per latest MCA records.
Charges
A charge with Canara Bank of Rs. 99.00 Lakh registered on 29 Jan 2020 with Charge ID 100326414 was modified on 18 Jul 2025.
Filing
Novorem Pharmaceuticals Private Limited has filed its annual Financial statements for the year ended 31 Mar 2025 with Roc Delhi I.
Charges
A charge with Canara Bank amounted to Rs. 99.00 Lakh with Charge ID 100326414 was registered on 29 Jan 2020.
Appointed
Fatima was appointed as Whole-Time Director.
Ceased
Nargis Khan ceased to be Director.
Appointed
Samiullah Khan was appointed as Managing Director.
Incorporation
28 Dec 2012
Novorem Pharmaceuticals Private Limited was registered on 28 Dec 2012 with Roc Delhi I & aged 13 years 9 months as per MCA records.
Frequently asked questions
Novorem Pharmaceuticals is an active private limited company based in New Delhi, Delhi, India. The company works in other wholesale, within the trading industry. It was incorporated on 28 December 2012 (14+ years old) and is registered under CIN U51397DL2012PTC246789.
Novorem Pharmaceuticals has 2 current directors:
- Samiullah Khan - Managing Director
- Fatima - Whole-Time Director
The latest financial statements of Novorem Pharmaceuticals on record with the MCA are for the year ended 31 March 2025. Its last annual general meeting was held on 30 July 2025. Year-wise statements from 2015 are in the company report.
The GSTIN of Novorem Pharmaceuticals is 09AAECN2302H1ZS, registered in Uttar Pradesh.
The CIN (Corporate Identification Number) of Novorem Pharmaceuticals is U51397DL2012PTC246789. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Novorem Pharmaceuticals was incorporated on 28 December 2012, making it 14+ years old. It is registered with the Registrar of Companies, Delhi.
Fatima was appointed as Whole-Time Director on 14 Sep 2018. Nargis Khan ceased to be Director on 14 Sep 2018. Samiullah Khan was appointed as Managing Director on 28 Dec 2012.
Yes, Novorem Pharmaceuticals is registered as a micro enterprise under Udyam registration (number: UDYAM-UP-76-0006686).
The registered office of Novorem Pharmaceuticals is at B – 10 Choudhary Complex D – 54 Main Road Batla House Jamia Naga, R, New Delhi, Delhi, India – 110025.
Novorem Pharmaceuticals operates in the trading industry, in the other wholesale segment.